Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-04-11
2006-04-11
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07026330
ABSTRACT:
Methods for treating patients having an early B cell derived acute lymphoblastic leukemia with rapamycin or a derivative thereof are provided. Also provided are methods for treating patients having an early B cell derived acute lymphoblastic leukemia with rapamycin or a derivative thereof in combination with an IL-7 inhibitor. Finally methods for preventing GVHD in ALL patients following a bone marrow transplant are disclosed.
REFERENCES:
patent: 4401653 (1983-08-01), Eng
patent: 4885171 (1989-12-01), Surendra et al.
patent: 5100899 (1992-03-01), Calne
patent: 5206018 (1993-04-01), Sehgal et al.
patent: 5362718 (1994-11-01), Skotnicki et al.
patent: 0 525 960 (1993-02-01), None
Ditonno, P., et al., “Regulatory effects of interleukin-7 on renal tumor infiltrating lymphocytes”, Urol. Res., vol. 20: p. 205-210, (1992).
Touw, I., et al., “Interleukin-7 Is a Growth Factor of Precursor B and T Acute Lymphoblastic Leukemia”, Blood, vol. 75: p. 2097-2101, (1990).
Wagner, E.F., et al., “A Pivotal Role of Cyclin D3 and Cyclin-Dependent Kinase Inhibitor p27 in the Regulation of IL-2-, IL-4-, or IL-10-Mediated Human B Cell Proliferation”, J. Immunology, 161: 1123-1131 (1998).
Majewski, M., et al., “The immunosuppressive macrolide RAD inhibits growth of human Esptein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders”, PNAS, vol. 97: p. 4285-4290, (2000).
Bauer, S.R., et al., “Clonal Relationship of the Lymphoblastic Cell Line P388 to the Macrophage Cell Line P388D1 as Evidenced by Immunoglobulin Gene Rearrangements and Expression of Cell Surface Antigens”, J. Immunology, vol. 136: p. 4695-4699 (1986).
Dawe, C.J., et al., “Morphologic and Biologic Expression of a Lymphoid Neoplasm of the Mouse In Vivo and In Vitro”, Scientific Proceedings, vol. 33: p. 603 (1957).
Eng., C.P., et al., “Activity of Rapamycin (AY-22, 989) Against Transplanted Tumors”, The Journal of Antibiotics, vol. 37: p. 1231-1237, (1984).
Muthukkumar, S., et al., “Rapamycin, a Potent Immunosuppresive Drug, Causes Programmed Cell Death in B Lymphoma Cells”, Transplantation, vol. 60: p. 264-270 (1995).
Aagaard-Tillery, K.M., et al., “Inhibition of Human B Lymphocyte Cell Cycle Progression and Differentiation by Rapamycin”, Cellular Immunology vol. 156: p. 493-507, (1994).
Calastretti, A., et al., “Rapamycin increases the cellular concentration of the BCL-2 protein and exerts an anti-apoptotic effect”, European J. of Cancer 37: 2121-2128 (2001).
Hidalgo, M., et al., “The rapamycin-sensitive signal transduction pathway as a tartet for cancer therapy”, Oncogene, vol. 19: 6680-6686 (2000).
Kay, J.E., et al., “Inhibition of T and B lymphocyte proliferation by rapamycin”, Immunology, vol. 72: p. 544-549 (1991).
Coleman, A.E., “Cytogenetic analysis of the biopotential murine pre-B cell lymphoma, P388, and its derivative macrophage-like tumor, P388D1, using SKY and CGH”, Leukemia, vol 13: p. 1592-1600 (1999).
ASCO Daily News, “New Molecular-Based Paradigms for Drug Development Yield Promising Results”, wysiwyg://107/http://www.asco.org/prof/and/2000/tue/NewTargets.htm; Accessed Jan. 17, 2002.
Appasamy, Biological and Clinical Implications of Interleukin-7 and Lymphopoiesis, Cytokines, Cellular and Molecular Therapy (1999), vol. 5, pp. 25-39.
Barata et al., Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27kip1, Blood (2001), vol. 98, No. 5, pp. 1524-1531.
Benjamin, et al., B Cell IL-7. Human B Cell Lines Constitutively Secrete IL-7 and Express IL-7 Receptors, Journal of Immunology (1994), vol. 152, pp. 4749-4757.
Bierer et al., Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin, PNAS (1990), vol. 87, pp. 9231-9235.
Brown et al., A mammalian protein targeted by G1-arresting rapamycin-receptor complex, Nature (1994), vol. 369, pp. 756-758.
Brunn et al., Phosphorylation of the Translational Repressor PHAS-1 by the Mammalian Target of Rapamycin, Science (1997), vol. 277, pp. 99-101.
Burnett et al., RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1, PNAS (1998), vol. 95, pp. 1432-1437.
Calne et al., Rapamycin for Immunosupression in Organ Allografting, The Lancet (1989), p. 227.
Castedo et al., Mammalian Target of Rapamycin (mTOR): Pro-and Anti-Apoptotic, Cell Death and Differentiation (2002), vol. 9, pp. 99-100.
Cavazzana-Calvo et al., Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease, Science (2000), vol. 288, pp. 669-672.
Cavazzana-Calvo et al., Gene therapy of severe combined immunodeficiencies, The Journal of Gene Medicine (2001), vol. 3, pp. 201-206.
Chen et al., A Putative Sirolimus (Rapamycin) Effector Protein, Biochemical and Biophysical Research Communications (1994), vol. 203, No. 1, pp. 1-7.
Chessells, Relapsed Lymphoblastic Leukaemia in Children: A continuing Challenge, British Journal of Haematology (1998), vol. 102, pp. 423-438.
Cronin et al., Role of μ Heavy Chain in B Cell development. I. Blocked B Cell Maturation But Complete Allelic Exclusion in the Absence of Iga/β, The Journal of Immunology, (1998), vol. 161, pp. 252-259.
Dadi et al., Interleukin-7 Receptor Mediates the Activation of Phosphatidylinosital-3 Kinase in Human B-Cell Precursors, Biochemical and Biophysical Research Communications (1993), vol. 192, No. 2, pp. 459-454.
Dadi et al., Activation of Phosphatidylinositol-3 Kinase by Ligation of the Interleukin-7 Receptor on Human Thymocytes, J. Clin. Invest. (1993), vol. 92, pp. 1559-1563.
Dadi et al., Activation of Phosphatidylinositol-3 Kinase by Ligation of the Interleukin-7 Receptor Is Dependent on Protein Tyrosine Kinase Activity, Blood (1994), vol. 84, No. 5, pp. 1579-1586.
Degiannis et al., Rapamycin Inhibits the In Vitro Release of Soluble CD23 by SAC/IL-2/IL-4- Activated Human Peripheral Blood B Lymphocytes, Transplantation (1995), vol. 59, No. 7, pp. 1076-1079.
Foss, et al., Frequent Expression of IL-7 Gene Transcripts in Tumor Cells of Classical Hodgkin's Disease, American Journal of Pathology, (1995), vol. 146, No. 1, pp. 33-39.
Dittel et al., The Growth response to IL-7 During Normal Human B Cell Ontogeny Is Restricted to B-Lineage Cells Expressing CD34, The Journal of Immunology (1995), vol. 154, pp. 58-67.
Dumont et al., Relationship Between Multiple Biologic Effects of Rapamycin and the Inhibition of pp70S6 Protein Kinase Activity. Analysis in Mutant Clones of a T Cell Lymphoma, Journal of Immunology (1994), vol. 152, pp. 992-1003.
Elit, CCI-779 Wyeth, Current Opinion in Investigational Drugs (2002), vol. 3, No. 8, pp. 1249-1253.
Ettenger et al., Safety and Efficacy of TOR Inhibitors in Pediatric Renal Transplant Recipients, American Journal of Kidney Diseases (2001), vol. 38, No. 4, pp. S22-S28.
Fischer, Severe combined immunodeficiencies (SCID), Clin. Exp. Immunol. (2000). vol. 122, pp. 143-149.
Fischer, Primary Immunodeficiency Diseases: Natural Mutant Models for Study of the Immune System, Scandinavian Journal of Immunology (2002), vol. 55, pp. 238-241.
Garber, Rapamycin's Resurrection: A New Way to Target the Cancer Cell Cycle, Journal of the National Cancer Institute (2001), vol. 93., No. 20, pp. 1517-1519.
Gaynon et al., Survival after Relapse in Childhood Acute Lymphoblastic Leukemia, Cancer (1998), vol. 82, No. 7, pp. 1387-1395.
Goodfellow et al., RET Gene and Its Implications for Cancer, Journal of the National Cancer Institute (1995), vol. 87, No. 20, pp. 1515-1523.
Guba et al., Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nature Medicine (2002), vol. 8, No. 2, pp. 128-135.
Hacein-Bey-Abina et al., Sustained Correction of X-Linked Severe Co
Brown Valerie I.
Grupp Stephan A.
Dann Dorfman Herrell and Skillman
Peselev Elli
Rigaut Kathleen D.
The Children's Hospital of Philadelphia
LandOfFree
Methods for treatment of acute lymphocytic leukemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of acute lymphocytic leukemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of acute lymphocytic leukemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3544909